'Thus the sample size is far too small to draw any meaningful...

First 75 Last

Share
Profile

Follow
cafa

8,917 Posts.

32

17/05/15

18:45

Post #: 15296360
Share

Originally posted by cafa ↑

Plasticd - done some research on the OS values, and would have to agree that it is unlikely to be any data at the conference. Ignore my previous logic - maybe just wishful thinking.

Resection rates. An interesting one. The ANN had a p value of 0.857. I'm not well versed in P values, but my understanding is that this represents 86% chance of a random outcome. Thus the sample size is far too small to draw any meaningful conclusion.

Now the Complete Response rate in the liver showing a 200% improvement with a P value of 0.02 is I believe a very good result. 6% be itself is no great number, but a 200% improvement with a high statistical result must be excellent news for a patient. Any oncologist talking to a patient about various treatments would be negligent if they did not refer to this dramatic improvement in outcomes. IMO.

@6186. I mentioned ability of centres and interventional radiologists as a possible constraint .
Thinking a little more I don't see this as an issue for some years. There are about 300 centres in the US. If each centre did 4 treatments per week, then that would be ~60,000 doses per year. A nice problem to have

Expand

'Thus the sample size is far too small to draw any meaningful conclusion.' This is completely wrong to say this. My bad, brain not in gear again!

SRX Price at posting: $28.00 Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

There are more pages in this discussion • 37 more messages in this thread...

First 75 Last

Add SRX (ASX) to my watchlist

'Thus the sample size is far too small to draw any meaningful...

Top Stories

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Featured News